{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:12:11Z","timestamp":1793236331923,"version":"4.5.0"},"reference-count":61,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["P30-CA046592"],"award-info":[{"award-number":["P30-CA046592"]}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radioactive iodine (RAI) has been one of the main treatments for hyperthyroidism since the 1940s, but its long-term safety, particularly regarding cancer risk, remains controversial. This study evaluated associations between RAI treatment and cancer incidence and mortality, including overall and site-specific cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study utilizing a University of Michigan de-identified electronic health record dataset. Adults (aged \u226518 years) newly diagnosed with hyperthyroidism between 2006 and 2019, without prior cancer, and treated with RAI, antithyroid medications, or thyroidectomy were included. Participants were followed until cancer diagnosis, death, or December 2022. Time-dependent Cox models estimated hazard ratios (HRs) and 95% CIs comparing RAI with other therapies using age-adjusted (age-adj) and multivariable (mv) models adjusting for demographics, lifestyle and clinical covariates. Sensitivity analysis stratified by cohort entry period, follow-up duration and restriction to \u22652 years of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 6435 participants contributing 52 909 person-years (mean follow up 8.2 years; range 0.5-17 years), with 487 incident cancers and 157 cancer deaths. RAI treatment was not associated with overall cancer incidence (mv HR = 1.02 [0.76-1.47], P = .734) or cancer mortality (mv HR = 0.81 [0.45-1.44], P = .471). However, RAI was significantly associated with increased breast cancer risk among women (mv HR = 2.24 [1.21-4.17], P = .011), and among postmenopausal women (mv HR = 2.65 [1.24-5.66], P = .011). An elevated pancreatic cancer mortality was observed in those with \u22652 years of follow-up (age-adj HR = 4.05 [1.01-16.20], P = .042).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RAI treatment was associated with increased breast cancer incidence but not overall cancer incidence or mortality. Findings for pancreatic cancer mortality were suggestive. These results support the importance of long-term safety monitoring among RAI-treated patients<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag058","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:43:59Z","timestamp":1771073039000},"page":"e1774-e1784","source":"Crossref","is-referenced-by-count":2,"title":["Associations between radioactive iodine treatment for hyperthyroidism and cancer incidence and mortality"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2702-3533","authenticated-orcid":false,"given":"Harry D","family":"Momo","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-1575","authenticated-orcid":false,"given":"Megan R","family":"Haymart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-9552","authenticated-orcid":false,"given":"Xu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8843-1416","authenticated-orcid":false,"given":"Alison M","family":"Mondul","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"1","key":"2026061619575807300_dgag058-B1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.21037\/gs.2019.11.01","article-title":"Hyperthyroidism","volume":"9","author":"Doubleday","year":"2020","journal-title":"Gland Surg"},{"issue":"11","key":"2026061619575807300_dgag058-B2","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A 2023 international survey of clinical practice patterns in the management of graves disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026061619575807300_dgag058-B3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026061619575807300_dgag058-B4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4158\/EP161607.OR","article-title":"A survey of clinical practice patterns in management of Graves disease in the Middle East and North Africa","volume":"23","author":"Beshyah","year":"2017","journal-title":"Endocr Pract"},{"issue":"4","key":"2026061619575807300_dgag058-B5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-56-4-590","article-title":"Leukemia in man following exposure to ionizing radiation","volume":"56","author":"Brill","year":"1962","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026061619575807300_dgag058-B6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V15.3.313.313","article-title":"Leukemia in Hiroshima atomic bomb survivors","volume":"15","author":"Heyssel","year":"1960","journal-title":"Blood"},{"issue":"5","key":"2026061619575807300_dgag058-B7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/thy.2008.0392","article-title":"Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis","volume":"19","author":"Sawka","year":"2009","journal-title":"Thyroid"},{"issue":"13","key":"2026061619575807300_dgag058-B8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies","volume":"40","author":"Pasqual","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026061619575807300_dgag058-B9","doi-asserted-by":"crossref","first-page":"djv314","DOI":"10.1093\/jnci\/djv314","article-title":"Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study","volume":"108","author":"Teng","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2026061619575807300_dgag058-B10","doi-asserted-by":"crossref","first-page":"13761","DOI":"10.1073\/pnas.2235592100","article-title":"Cancer risks attributable to low doses of ionizing radiation: assessing what we really know","volume":"100","author":"Brenner","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026061619575807300_dgag058-B11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/00004032-199606000-00006","article-title":"Effects of low doses of radiation","volume":"70","author":"Fry","year":"1996","journal-title":"Health Phys"},{"key":"2026061619575807300_dgag058-B12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/B978-0-12-035405-4.50010-4","article-title":"Radiation-induced life-shortening and premature aging","volume":"5","author":"Walburg","year":"1975","journal-title":"Adv Radiat Biol"},{"issue":"6","key":"2026061619575807300_dgag058-B13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/09553008914551081","article-title":"UNSCEAR report (1988) sources, effects and risks of ionising radiation. United Nations Scientific Committee on the effects of atomic radiation, 1988. Report to the general assembly, with annexes","volume":"55","author":"Scott","year":"1989","journal-title":"Int J Radiat Biol"},{"issue":"4","key":"2026061619575807300_dgag058-B14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1590\/S1415-475738420150019","article-title":"Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer","volume":"38","author":"Borrego-Soto","year":"2015","journal-title":"Genet Mol Biol"},{"key":"2026061619575807300_dgag058-B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.dnarep.2014.02.001","article-title":"Genetic factors in individual radiation sensitivity","volume":"16","author":"Hornhardt","year":"2014","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"2026061619575807300_dgag058-B16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1101\/gr.122044.111","article-title":"Genetic variation in radiation-induced cell death","volume":"22","author":"Smirnov","year":"2012","journal-title":"Genome Res"},{"issue":"2","key":"2026061619575807300_dgag058-B17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0027-5107(83)90172-0","article-title":"The exchange hypothesis for the formation of chromatid aberrations: an experimental test using bleomycin","volume":"107","author":"Duncan","year":"1983","journal-title":"Mutat Res"},{"key":"2026061619575807300_dgag058-B18","first-page":"367","volume-title":"The Breakage-and-Reunion Theory and the Exchange Theory for Chromosomal Aberrations Induced by Ionizing Radiations: A Short History","author":"Revell","year":"1974"},{"issue":"8","key":"2026061619575807300_dgag058-B19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/78630","article-title":"The mammary gland iodide transporter is expressed during lactation and in breast cancer","volume":"6","author":"Tazebay","year":"2000","journal-title":"Nat Med"},{"issue":"5","key":"2026061619575807300_dgag058-B20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00204-020-02752-z","article-title":"Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast","volume":"94","author":"Helm","year":"2020","journal-title":"Arch Toxicol.Springer"},{"issue":"3","key":"2026061619575807300_dgag058-B21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ije\/11.3.218","article-title":"Cancer incidence following treatment of hyperthyroidism","volume":"11","author":"Hoffman","year":"1982","journal-title":"Int J Epidemiol"},{"issue":"12","key":"2026061619575807300_dgag058-B22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jama.1968.03140380059014","article-title":"Incidence of leukemia following treatment of hyperthyroidism","volume":"205","author":"Saenger","year":"1968","journal-title":"JAMA"},{"issue":"10","key":"2026061619575807300_dgag058-B23","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.22635","article-title":"Increased cancer incidence after radioiodine treatment for hyperthyroidism","volume":"109","author":"Metso","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"2026061619575807300_dgag058-B24","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1210\/jc.2015-1874","article-title":"Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism","volume":"100","author":"Ry\u00f6di","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"2026061619575807300_dgag058-B25","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/83.15.1072","article-title":"Cancer risk after iodine-131 therapy for hyperthyroidism","volume":"83","author":"Holm","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"9170","key":"2026061619575807300_dgag058-B26","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","article-title":"Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study","volume":"353","author":"Franklyn","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"2026061619575807300_dgag058-B27","first-page":"63","article-title":"Breast cancer following iodine-131 therapy for hyperthyroidism","volume":"70","author":"Hoffman","year":"1983","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2026061619575807300_dgag058-B28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a114900","article-title":"Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women","volume":"127","author":"Goldman","year":"1988","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2026061619575807300_dgag058-B29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.2019.0205","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study","volume":"30","author":"Gronich","year":"2020","journal-title":"Thyroid"},{"issue":"5","key":"2026061619575807300_dgag058-B30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2967\/jnumed.123.266531","article-title":"Cancer risk in Graves disease with radioactive 131 I treatment: a nationwide cohort study","volume":"65","author":"Kim","year":"2024","journal-title":"J Nucl Med"},{"issue":"6","key":"2026061619575807300_dgag058-B31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jcem-38-6-976","article-title":"Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study","volume":"38","author":"Dobyns","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619575807300_dgag058-B32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism","volume":"280","author":"Ron","year":"1998","journal-title":"JAMA"},{"issue":"8","key":"2026061619575807300_dgag058-B33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","article-title":"Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2026061619575807300_dgag058-B34","doi-asserted-by":"crossref","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","article-title":"Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism","volume":"3","author":"Kitahara","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2026061619575807300_dgag058-B35","doi-asserted-by":"crossref","first-page":"e1901","DOI":"10.1210\/clinem\/dgz305","article-title":"Association of radioactive iodine treatment of hyperthyroidism with cancer mortality: an unjustified warning?","volume":"105","author":"Hindi\u00e9","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026061619575807300_dgag058-B36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2967\/jnumed.119.234849","article-title":"Radioactive iodine treatment and cancer mortality in hyperthyroid patients: questioning standard clinical practice requires indisputable scientific data","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"issue":"11","key":"2026061619575807300_dgag058-B37","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2967\/jnumed.119.235929","article-title":"There is no association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"60","author":"Greenspan","year":"2019","journal-title":"J Nucl Med"},{"issue":"10","key":"2026061619575807300_dgag058-B38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/RLU.0000000000002792","article-title":"Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot","volume":"44","author":"Tulchinsky","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2026061619575807300_dgag058-B39","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1210\/jc.2017-02599","article-title":"Benign thyroid diseases and risk of thyroid cancer: a nationwide cohort study","volume":"103","author":"Kitahara","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619575807300_dgag058-B40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/EJE-15-0989","article-title":"Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study","volume":"174","author":"S\u00f8gaard","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026061619575807300_dgag058-B41","author":"AI & Digital Health Innovation"},{"key":"2026061619575807300_dgag058-B42","author":"Michigan Department of Health and Human Services"},{"issue":"5","key":"2026061619575807300_dgag058-B43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026061619575807300_dgag058-B44","author":"Ruhl"},{"key":"2026061619575807300_dgag058-B45","doi-asserted-by":"crossref","unstructured":"Momo HD, Haymart MR, Shi X, Mondul AM. Supplementary tables for \u201cassociations between radioactive iodine treatment for hyperthyroidism and cancer\u201d. Figshare. Published online December 2025. doi:10.6084\/m9.figshare.30899393.v1","DOI":"10.1210\/clinem\/dgag058"},{"key":"2026061619575807300_dgag058-B46","first-page":"175","volume-title":"Tumour Site Concordance and Mechanisms of Carcinogenesis","author":"Hill","year":"2019"},{"key":"2026061619575807300_dgag058-B47","first-page":"1","volume-title":"Mammary Stem Cells: Methods and Protocols","author":"Luo","year":"2015"},{"issue":"1","key":"2026061619575807300_dgag058-B48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/er.2001-0029","article-title":"The sodium\/iodide symporter (NIS): characterization, regulation, and medical significance","volume":"24","author":"Doha\u0301n","year":"2003","journal-title":"Endocr Rev"},{"issue":"2","key":"2026061619575807300_dgag058-B49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/thy.1997.7.199","article-title":"Radiation dose to patients and relatives incident to 131 I therapy","volume":"7","author":"Zanzonico","year":"1997","journal-title":"Thyroid"},{"issue":"6","key":"2026061619575807300_dgag058-B50","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/er.2012-1030","article-title":"Radioiodine therapy in benign thyroid diseases: effects, Side effects, and factors affecting therapeutic outcome","volume":"33","author":"Bonnema","year":"2012","journal-title":"Endocr Rev"},{"key":"2026061619575807300_dgag058-B51","volume-title":"Preventing Breast Cancer: the Story of a Major, Proven, Preventable Cause of This Disease","author":"Gofman","year":"1996","edition":"2nd ed"},{"issue":"4","key":"2026061619575807300_dgag058-B52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clon.2011.01.159","article-title":"Medical exposure to radiation and thyroid cancer","volume":"23","author":"Schonfeld","year":"2011","journal-title":"Clin Oncol"},{"issue":"1","key":"2026061619575807300_dgag058-B53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4048\/jbc.2016.19.1.18","article-title":"Caffeic acid phenethyl ester increases radiosensitivity of estrogen receptor-positive and -negative breast cancer cells by prolonging radiation-induced DNA damage","volume":"19","author":"Khoram","year":"2016","journal-title":"J Breast Cancer"},{"issue":"9","key":"2026061619575807300_dgag058-B54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5306\/wjco.v2.i9.329","article-title":"DNA damage and breast cancer","volume":"2","author":"Davis","year":"2011","journal-title":"World J Clin Oncol"},{"issue":"5","key":"2026061619575807300_dgag058-B55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/carcin\/bgg037","article-title":"DNA damage and breast cancer risk","volume":"24","author":"Smith","year":"2003","journal-title":"Carcinogenesis"},{"issue":"2","key":"2026061619575807300_dgag058-B56","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/bcr1668","article-title":"Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study","volume":"9","author":"Broeks","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2026061619575807300_dgag058-B57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-016-0709-1","article-title":"Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation","volume":"18","author":"Baert","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2026061619575807300_dgag058-B58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ccr.2011.03.011","article-title":"Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type","volume":"19","author":"Nguyen","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"2026061619575807300_dgag058-B59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/jpm12050725","article-title":"Modulation of secondary cancer risks from radiation exposure by sex, age and gonadal hormone Status: progress, opportunities and challenges","volume":"12","author":"Biegon","year":"2022","journal-title":"J Pers Med. MDPI"},{"issue":"1-2","key":"2026061619575807300_dgag058-B60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mce.2010.02.007","article-title":"Genetics and phenomics of hypothyroidism and goiter due to NIS mutations","volume":"322","author":"Spitzweg","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2026061619575807300_dgag058-B61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/hum.2006.17.661","article-title":"Adenovirus-mediated and targeted expression of the sodium\u2013iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors","volume":"17","author":"Dwyer","year":"2006","journal-title":"Hum Gene Ther"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag058\/66958744\/dgag058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1774\/66958744\/dgag058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1774\/66958744\/dgag058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:58:10Z","timestamp":1781654290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/e1774\/8488695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag058","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,17]]}}}